Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved

Autores/as

DOI:

https://doi.org/10.11606/s1518-8787.2019053000879

Palabras clave:

Anti-Bacterial Agents, Prescription Drug Overuse, legislation & jurisprudence, Drug Resistance, Microbial, Drug Monitoring, Pharmacovigilance

Resumen

OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS: A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). RESULTS: The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). CONCLUSIONS: The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism.

Publicado

2019-02-07

Número

Sección

Artigos Originais

Cómo citar

Costa, J. M. da, Moura, C. S. de, Pádua, C. A. M. de, Vegi, A. S. F., Magalhães, S. M. S., Rodrigues, M. B., & Ribeiro, A. Q. (2019). Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved. Revista De Saúde Pública, 53, 68. https://doi.org/10.11606/s1518-8787.2019053000879